Affiliations: [a] Laboratory of Neuroscience, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| [b] Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel
| [c] Department of Hematology, Hadassah University Hospital, Jerusalem, Israel
Correspondence:
[*]
Correspondence to: Prof. Bilha Fischer, Department of Chemistry, Bar-Ilan University, Ramat-Gan 52900, Israel. Tel.: +927 3 5318303; E-mail: [email protected] and Prof. Daniel Offen, Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva 49100, Israel. E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Background: Metal-ion-chelation was suggested to prevent zinc and copper ions-induced amyloid-β (Aβ) aggregation and oxidative stress, both implicated in the pathophysiology of Alzheimer’s disease (AD). In a quest for biocompatible metal-ion chelators potentially useful for AD therapy, we previously tested a series of nucleoside 5’-phosphorothioate derivatives as agents for decomposition of Cu(I)/Cu(II)/Zn(II)-Aβ-aggregates, and as inhibitors of OH radicals formation in Cu(I) or Fe(II) /H2O2 solution. Specifically, in our recent study we have identified 2-SMe-ADP(α-S), designated as SAS, as a most promising neuroprotectant. Objective: To further explore SAS ability to protect the brain from Aβ toxicity both in vitro and in vivo. Methods: We evaluated SAS ability to decompose or inhibit the formation of Aβ42-M(II) aggregates, and rescue primary neurons and astrocytes from Aβ42 toxicity. Furthermore, we aimed at exploring the therapeutic effect of SAS on behavioral and cognitive deficits in the 5XFAD mouse model of AD. Results: We found that SAS can rescue primary culture of neurons and astrocytes from Aβ42 toxicity and to inhibit the formation and dissolve Aβ42-Zn(II)/Cu(II) aggregates. Furthermore, we show that SAS treatment can prevent behavioral disinhibition and ameliorate spatial working memory deficits in 5XFAD mice. Notably, the mice were treated at the age of 2 months, before the onset of AD symptoms, for a duration of 2 months, while the effect was demonstrated at the age of 6 months. Conclusion: Our results indicate that SAS has the potential to delay progression of core pathological characteristics of AD in the 5XFAD mouse model.
